Serum Biomarker for Cardiovascular Disease Risk Assessment in Patients With Diabetic Nephropathy

Area of Science:

• Endocrinology and Metabolism
• Cardiology
• Nephrology

Background:

• Diabetic nephropathy (DN) and coronary artery disease (CAD) are common, serious complications of diabetes.
• Understanding biomarkers that link these conditions is crucial for patient management.
• Sirtuin 1 (SIRT1) is a protein involved in metabolic regulation and cellular stress responses.

Purpose of the Study:

• To compare serum sirtuin 1 levels in patients with diabetic nephropathy, with and without co-existing coronary artery disease.
• To investigate the potential of serum sirtuin 1 as a biomarker for coronary artery disease in diabetic nephropathy patients.

Main Methods:

• A cross-sectional study included 108 diabetic nephropathy patients, with 54 having diagnosed coronary artery disease.
• Serum sirtuin 1 levels were measured using Enzyme Linked Immunosorbent Assay (ELISA).
• Statistical analysis and Receiver Operating Characteristic (ROC) curve analysis were performed.

Main Results:

• Mean serum sirtuin 1 levels were 2.27 ng/ml in DN patients with CAD and 2.55 ng/ml in those without.
• The difference in serum sirtuin 1 levels between the groups was not statistically significant (p = 0.063).
• ROC analysis indicated sirtuin 1 is not a robust biomarker for predicting CAD in DN patients (AUC = 0.604).

Conclusions:

• Serum sirtuin 1 levels do not differ significantly between diabetic nephropathy patients with and without coronary artery disease.
• Sirtuin 1 is unlikely to be a strong indicator of the presence or severity of coronary artery disease in this population.